 Home > Active Ingredient News > Antitumor Therapy > Front Oncol: FOLFOX regimen hepatic arterial infusion chemotherapy (HAIC) combined with sorafenib improves the prognosis of advanced hepatocellular carcinoma compared with HAIC alone

Front Oncol: FOLFOX regimen hepatic arterial infusion chemotherapy (HAIC) combined with sorafenib improves the prognosis of advanced hepatocellular carcinoma compared with HAIC alone

 Last Update: 2021-10-10
 Source: Internet
 Author: User

Tags

royal legal group

drawing bases group

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Liver carcinoma (HCC) is one of the most common malignant tumors, is the second leading cause of cancer-related deaths
.

Sorafenib is often used to treat patients with advanced HCC, but the individual heterogeneity varies greatly, and the median overall survival (OS) is only 6.

Cell carcinoma (HCC) is one of the most common malignant tumors in the world and the second leading cause of cancer-related deaths

This is a retrospective study that included 225 eligible patients, of which 126 were HAIC alone and 99 were HAIC+sorafenib (soraHAIC group)
.

Using propensity score matching method, there were 93 patients in each group

This is a retrospective study that included 225 eligible patients, of which 126 were HAIC alone and 99 were HAIC+sorafenib (soraHAIC group)

Before matching, the median OS of the soraHAIC group was 12.

OS and PFS before and after matching

In the propensity score matching cohort, the median OS of the soraHAIC group was 13.
0 months (95% CI, 10.
4-15.
5), while the median OS of the HAIC group was 10.
0 months (95% CI, 8.
6-11.
4) (HR= 0.
67; 95%CI 0.
49-0.
93; P = 0.
015)
.

The median PFS of the soraHAIC group was 6.

In the propensity score matching cohort, the median OS of the soraHAIC group was 13.

The multivariate analysis of the pre- and post-matching cohorts found that soraHAIC treatment was an independent survival factor

Prognostic factors

The incidence of any grade of hand-foot skin reaction, rash, vomiting, diarrhea, and nausea in the soraHAIC group was significantly higher than that in the HAIC group (p <0.
05)
.

Grade 3-4 hand-foot skin reactions were more common in the soraHAIC group (P<0.

The incidence of any grade of hand-foot skin reaction, rash, vomiting, diarrhea, and nausea in the soraHAIC group was significantly higher than that in the HAIC group (p <0.

Adverse events

In summary, studies have shown that compared with HAIC alone, HAIC combined with sorafenib can improve the overall survival and progression-free survival of advanced liver cancer
.

Studies have shown that compared with HAIC alone, HAIC combined with sorafenib can improve the overall survival and progression-free survival of advanced liver cancer

Original source:

Liang RB, Zhao Y, He MK, et al (2021) Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma.
Front.
Oncol.
11:619461.
doi: 10.
3389/fonc .
2021.
619461

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.